MOC Molecure S.A.

GPW · PL · Healthcare · Biotechnology · molecure.com

7.520PLN+6.21%Mkt Cap: 44.33M $P/E: —Today

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a ch…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap44.33M USD

Enterprise Value32.67M USD

Revenue (TTM)1.65M USD

Gross Profit-863.37K USD

Net Income (TTM)-7.92M USD

Revenue/Share0.32 PLN

Last Price7.520 PLN

Fiscal Year EndDec 2025

MR QuarterDec 2025

Employees—

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLONCTH00011

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-8.25

EV/Revenue19.79

P/S26.85

P/B1.63

EPS (TTM)-0.99

EPS (Forward)—

52W Range

4.98062% of range9.060

52W High9.060 PLN

52W Low4.980 PLN

Profitability

Gross Margin-253.98%

Oper. Margin-61.33%

EBITDA Margin-239.77%

Profit Margin-240.64%

ROE-30.26%

ROA-27.51%

Growth

Revenue Growth29.00%

Earnings Growth—

Cash Flow & Leverage

Operating CF-14.43M USD

CapEx (TTM)6.02M USD

FCF Margin—

FCF Yield—

Net Debt-4.27M USD

Net Debt/EBITDA1.08

Balance Sheet

Debt/Equity0.07

Current Ratio—

Quick Ratio—

Book Value/Sh4.34 PLN

Cash/Share1.09 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)12.45 PLN

Upside (mean)+65.6%

Target Range9.900 PLN – 15.00 PLN

9.900+65.6% to mean15.00

# Analysts2

Ownership

Shares Out.24.72M

Float16.30M

Insiders29.29%

Institutions9.31%

Technical

SMA 506.576 (+14.3%)

SMA 2006.327 (+18.9%)

Beta1.00

S&P 52W Chg14.58%

Avg Vol (30d)42.52K

Avg Vol (10d)61.83K

Technical Indicators

RSI (14)73.2

MACD0.3534

MACD Signal0.2630

MACD Hist.+0.0904

BB Upper7.370 PLN

BB Middle6.245 PLN

BB Lower5.119 PLN

BB Width36.03%

ATR (14)0.3742 PLN

Vol Ratio (20d)0.93x